Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Shares Traded Last Trade
  3.60 1.99% 184.80 573,820 16:35:04
Bid Price Offer Price High Price Low Price Open Price
182.00 185.00 185.00 177.40 179.80
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 25.39 15.54 2.34 79.0 1,237
Last Trade Time Trade Type Trade Size Trade Price Currency
17:55:33 O 67 178.395 GBX

Syncona (SYNC) Latest News

More Syncona News
Syncona Investors    Syncona Takeover Rumours

Syncona (SYNC) Discussions and Chat

Syncona Forums and Chat

Date Time Title Posts
20/11/202221:43Wellcome to Syncona652
02/5/202022:59Synchronica - Major management change heralds new strategy2
28/1/201702:52Welcome to Syncona 2
20/12/201615:28Synchronica - Mobile Technology - 20124,755
08/3/201200:18Synchronica SYNC - Mobile Phone Technology - 20113,347

Add a New Thread

Syncona (SYNC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Syncona trades in real-time

Syncona (SYNC) Top Chat Posts

Top Posts
Posted at 27/11/2022 08:20 by Syncona Daily Update
Syncona Limited is listed in the Equity Investment Instruments sector of the London Stock Exchange with ticker SYNC. The last closing price for Syncona was 181.20p.
Syncona Limited has a 4 week average price of 169p and a 12 week average price of 158.20p.
The 1 year high share price is 224.50p while the 1 year low share price is currently 154p.
There are currently 669,329,324 shares in issue and the average daily traded volume is 343,644 shares. The market capitalisation of Syncona Limited is £1,236,920,590.75.
Posted at 20/11/2022 21:43 by tiger blue
I agree that it was an ambitious statement, but not one they had to make and at this stage unlikely to move the dial much on the share price. They are however serious people who know their sector well, with excellent contacts to enable early access to good science, and it was intriguing that they made it at all. I think they have learned a lot since launch, but still delivered a portfolio IRR of 26% to date, and stepping up the number of company launches with additional recruitment should give a boost. Despite some excellent exits NASDAQ has not been a happy place for their quoted companies, hence what reads as a shift to holding privately to exit with 'like minded' investors. That's not necessarily a bad thing, as Gyroscope had the float badly handled and pulled, but despite that soon after got a nice bid from Novartis. That was their second retinal area sale and they are back in with another new retinal venture. At the end of the day I am there on the basis that anywhere below nav they look on the cheap side, and if they get somewhere close to their target I will be well rewarded. Incidentally, if my use of the compound calculator is correct, it would take a 15% compound return to get to £5 billion over the 10 years. Yes, they have the drag of the capital pool to contend with, but given the portfolio IRR they have achieved to date it's not out of the question.
Posted at 20/11/2022 20:59 by rambutan2
So was I, so I watched the webcast and have to say that no real guidance was given beyond that the sector itself has tremendous opportunities, and that SYNC is upping its game a tad by taking on more staff. I was hoping that in Q&A at the end one of the analysts would ask the (obvious) question, but none did. They are not upping the amount they invest pa, at least for the time being, and they are intent on keeping a big cash balance - which is sensible but a big drag on returns. Of course, it could be that they are supremely confident one of their current port cos is going to go to the moon, and the beauty of bio investing is that success can bring huge value add. Hmmm...
Posted at 20/11/2022 10:34 by lomax99
The NAV per share has approx. doubled in the last decade and is up c. 27% over the last 5 years, any particular reason why the next 10 years is going to show, frankly, staggering comparative outperformance? Genuinely interested!
Posted at 17/11/2022 10:19 by tiger blue
Just listened in on the results presentation, very ambitious targets to grow nav to £5bn over next 10 years from current £1.2bn. Biotech has been and remains a horrible sector for momentum at the moment, but as a tuckaway these look cheap and sentiment alone has been a big driver of the share price. This touched 300p when assets were 215-220p, assets now 203p and shares 175p - with that discount and their ability to incubate companies from interesting science to product development/sale I have added another 25k today.
Posted at 16/11/2022 18:35 by chc15
Lol anyway back to sync..drop on no news?
Posted at 16/6/2022 15:06 by rambutan2
Finals out, all in all, quite good:

The second half of CY2021 was marked by significant volatility across equity markets globally. This uncertainty has carried on into 2022, compounded by concerns around inflation, interest rates and Russia's invasion of Ukraine and the ongoing humanitarian crisis. This has impacted investor sentiment towards risk assets. We have seen a macro rotation away from growth stocks, impacting both valuations and financings of biotech companies, especially smaller, earlier stage companies. As market volatility has increased, the Syncona team continues to carefully review the requirements of each of our portfolio companies and our capital pool to ensure that our Company is well positioned to navigate continuing challenging markets. Our balance sheet provides us with a strategic advantage, and the team's expertise and rigorous approach to risk management means we continue to take a disciplined approach to capital allocation across a well-funded portfolio and exciting pipeline.

Syncona ended the year with net assets of GBP1,309.8 million or 194.4p per share, a 0.3 per cent return in the year (31 March 2021: net assets of GBP1,300.3 million, NAV per share of 193.9p, 4.4 per cent return), despite the wider market backdrop for life science companies, which saw the NASDAQ Biotechnology Index decline 12 per cent during the period. The significant NAV uplift achieved through the sale of Gyroscope to Novartis and multiple successful private financings offset the decline in share prices of our three listed companies, Autolus, Freeline and Achilles. We recognise that the performance of these listed companies has been disappointing for our shareholders. Our team have worked closely with portfolio company management teams to support them as they continue to execute their development plans. Similarly, the challenging market conditions have also impacted Syncona's share price performance in the financial year, which has been disappointing. Whilst the market environment for early stage biotech companies continues to be challenging, our listed companies are funded to deliver clinical data which represent key milestones for their businesses, and we believe Syncona is well positioned to deliver growth over the long term.

https://uk.advfn.com/stock-market/london/syncona-SYNC/share-news/Syncona-Limited-Final-Results/88377324

Posted at 28/4/2022 19:24 by rambutan2
And to balance things out:

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, today announces that it has committed GBP15 million in an oversubscribed GBP75.5 million Series B financing in OMass Therapeutics ("OMass"), a biotechnology company that identifies medicines against highly validated target ecosystems. Syncona was a co-investor in this financing round, which was led by new investors GV, Northpond and Sanofi Ventures. Existing investors Oxford Science Enterprises and Oxford University also joined the round.

OMass, an Oxford University spin out, is developing small molecule drugs to treat rare diseases and immunological conditions. The company has a unique approach to the way it finds new medicines. It uses its proprietary drug discovery platform, OdyssION(TM), to more accurately interrogate the target and how it interacts with its native ecosystem. These observations provide potentially critical information that can increase the chances of finding highly effective small molecule medicines that will be successful in clinical trials.

This latest financing brings the total amount that OMass has raised to GBP119 million. These proceeds will be used to advance OMass' small molecule portfolio towards clinical trials. This includes progressing the development of small molecule drugs to treat Congenital Adrenal Hyperplasia, Inflammatory Bowel Disease and other inflammatory and rare diseases.

Following the Series B financing, Syncona has revalued its existing investment which has resulted in a 32% uplift in the value of its stake in OMass. Including the drawdown of the first tranche of Syncona's Series B investment of GBP15 million, Syncona's holding value of OMass is now GBP44 million. On drawdown of the full Series B financing, Syncona's ownership stake in OMass will be 31 per cent.

Edward Hodgkin, Chair of OMass and Partner at Syncona said: "We are pleased with this financing round which will support OMass as it looks to progress its pipeline of small molecule drugs. The strength of this global group of top tier life science investors reflects confidence in the company's technology and supports our ambition to build a sustainable therapeutics business that has the potential to develop novel drugs in areas of high unmet medical need . This financing represents a further validation of the ability of Syncona's portfolio companies to attract high quality syndicates, to fund them over the long-term."

https://uk.advfn.com/stock-market/london/syncona-SYNC/share-news/Syncona-Limited-Syncona-invests-in-GBP75-5-million/87933959

Posted at 01/3/2022 13:29 by tiger blue
Back in today at 167.5, having sold out of my remaining shares at 225 when the Gyroscope NASDAQ float was pulled. Since then Gyroscope has of course been sold but the share price has still tanked. I have recalculated nav based on the quoted movements since the last valuation date (dec 31), and make it c. 192.4p. SYNC has traded at a premium to nav in excess of 40% in the past. That looked frothy but I do feel that given their ability to create value the shares now look cheap on a discount of 12%. Autolus/Freeline/Achilles have all been grim on NASDAQ but the trio now only represent less than 7.5% of the nav so cannot do much more damage, and one or more could possibly spring a surprise. One big unknown is the future milestone payments due from Gyroscope, which may be up to £249.4 million, but which are discounted for risk/time etc by Syncona to a current value of £47.5m, which looks a conservative approach. Hard buying anything in these markets, but you have to dip a toe in sometimes!
Posted at 14/11/2021 16:12 by sev22
The Syncona Investment Trust, a member of Interactive Investor’s ACE 40 rated list of ethical investments, has reported its latest half-yearly results (11th November 2021):

Syncona Ord (SYNC) investment trust, which invests in life science companies, reported a decline in net asset value of 11.4% for the first six months of its financial year – from the end of March to the end of September.

Over this period, the trust reported that its net assets sat at £1.15 billion, down from £1.3 billion at the end of March 2021.

Figures from FE Analytics show that over this period its share price total return was a loss of 33.6%, suffering from its high premium notably declining.

The decline, the report notes, was driven predominantly by the decline in the share price of two of the trust’s listed holdings, Freeline Therapeutics Holdings ADR FRLN
and Achilles Therapeutics ADR ACHL.

Freeline’s poor performance is put down to “operational challenges” owing to the Covid-19 pandemic. Syncona says these concerns have now been addressed.

Achilles’ share price decline was driven by “market sentiment towards cell and gene therapies”. Syncona says that it believes the business is performing well and in line with expectations.

The trust’s strategy is to establish, build and fund companies to turn exceptional science into a dynamic portfolio of global leaders in life sciences. The aim is for the companies to deliver their product to market. The trust has a long-term target of owning between 15 and 20 companies. It currently has 10.

Martin Murphy, chief executive of Syncona Investment Management Limited, said: “While we are disappointed by the decline in NAV during the period, we are continuing to build a diverse portfolio across the development cycle and therapeutic areas and remain confident in our companies' potential. The substantial capital that a number of our companies have accessed so far this year validate the significant opportunity ahead for them.”

The trust also said that it planned to deploy another £100 million to £175 million into both existing companies and new opportunities this year.

Murphy said: “With clinical data the key driver of value and risk for Syncona, we believe our companies are well positioned and on track to further validate our model and strategy in the next 12 months with the potential for a rich seam of data.”

The trust is a member of Interactive Investor’s ACE 40 rated list of ethical investments. It was placed under formal review in the summer due to the volatility of its share price, but it kept its place on the list.

Dzmitry Lipski, head of funds research at Interactive Investor, notes: “We remain positive on the trust outlook and see it as a strong choice for adventurous investors prepared to tolerate high volatility in the short term, but potentially reap rewards over the longer term.

Posted at 26/7/2019 08:04 by luxaeterna1
The SYNC share price continues a strong trend, while the AUTL price shows weakness. Perhaps related to Woodford's holding (forced sell?) and market waiting for the Q3/Q4 CAR-T updates.
Syncona share price data is direct from the London Stock Exchange
Your Recent History
LSE
SYNC
Syncona
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221128 02:02:36